title: [Single vs double stem cell transplantation for the treatment of multiple myeloma].
abstract: High-dose therapy followed by autologous stem cell transplantation (ASCT) is the current optimal up-front treatment for younger, transplantation-eligible multiple myeloma patients, although the efficacy of double (tandem) ASCT remains unclear in previously untreated patients. According to published randomized trials and recent meta-analysis, double ASCT improved event-free survival and overall survival compared with single ASCT but increased transplant-related mortality. Double ASCT is now recommended for the treatment of patients who failed to achieve a very good response or better after the first transplantation. Further studies will be required to determine whether double ASCT is still needed in patients treated with highly effective novel agents.
authors.forename: Hideto
authors.initials: H
authors.lastname: Tamura
mesh_terms: D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D033581:Stem Cell Transplantation / Q000379:methods*; D014182:Transplantation, Autologous